{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:42:14Z","timestamp":1790682134297,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/cdd.2016.150","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T15:32:51Z","timestamp":1486740771000},"page":"500-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death"],"prefix":"10.1038","volume":"24","author":[{"given":"Florent","family":"Dufour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Rattier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Picarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei Alexandru","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymeric","family":"Morl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Batoul","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Marcion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Causse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Szegezdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Michael","family":"Zajonc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Seigneuric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tijani","family":"Gharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Picaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Herlem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris Alan","family":"Benedict","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Micheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,10]]},"reference":[{"key":"BFcdd2016150_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0968-0004(01)01995-8","volume":"27","author":"JL Bodmer","year":"2002","unstructured":"Bodmer JL, Schneider P, Tschopp J . The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27: 19\u201326.","journal-title":"Trends Biochem Sci"},{"key":"BFcdd2016150_CR2","doi-asserted-by":"publisher","first-page":"4752","DOI":"10.1038\/onc.2010.221","volume":"29","author":"F Gonzalvez","year":"2010","unstructured":"Gonzalvez F, Ashkenazi A . New insights into apoptosis signaling by Apo2L\/TRAIL. Oncogene 2010; 29: 4752\u20134765.","journal-title":"Oncogene"},{"key":"BFcdd2016150_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","volume":"127","author":"C Falschlehner","year":"2009","unstructured":"Falschlehner C, Schaefer U, Walczak H . Following TRAIL's path in the immune system. Immunology 2009; 127: 145\u2013154.","journal-title":"Immunology"},{"key":"BFcdd2016150_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1517\/14728222.11.10.1299","volume":"11","author":"D Merino","year":"2007","unstructured":"Merino D, Lalaoui N, Morizot A, Solary E, Micheau O . TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007; 11: 1299\u20131314.","journal-title":"Expert Opin Ther Targets"},{"key":"BFcdd2016150_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/35008667","volume":"2","author":"JL Bodmer","year":"2000","unstructured":"Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241\u2013243.","journal-title":"Nat Cell Biol"},{"key":"BFcdd2016150_CR6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nrd2637","volume":"7","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A . Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001\u20131012.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcdd2016150_CR7","doi-asserted-by":"publisher","first-page":"7046","DOI":"10.1128\/MCB.00520-06","volume":"26","author":"D Merino","year":"2006","unstructured":"Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O . Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046\u20137055.","journal-title":"Mol Cell Biol"},{"key":"BFcdd2016150_CR8","doi-asserted-by":"publisher","first-page":"e19679","DOI":"10.1371\/journal.pone.0019679","volume":"6","author":"N Lalaoui","year":"2011","unstructured":"Lalaoui N, Morle A, Merino D, Jacquemin G, Iessi E, Morizot A et al. TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT. PLoS One 2011; 6: e19679.","journal-title":"PLoS One"},{"key":"BFcdd2016150_CR9","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/nm1627","volume":"13","author":"KW Wagner","year":"2007","unstructured":"Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L\/TRAIL. Nat Med 2007; 13: 1070\u20131077.","journal-title":"Nat Med"},{"key":"BFcdd2016150_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/0966-842X(96)81503-4","volume":"4","author":"WJ Britt","year":"1996","unstructured":"Britt WJ . Vaccines against human cytomegalovirus: time to test. Trends Microbiol 1996; 4: 34\u201338.","journal-title":"Trends Microbiol"},{"key":"BFcdd2016150_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.tim.2005.02.009","volume":"13","author":"L Pereira","year":"2005","unstructured":"Pereira L, Maidji E, McDonagh S, Tabata T . Insights into viral transmission at the uterine-placental interface. Trends Microbiol 2005; 13: 164\u2013174.","journal-title":"Trends Microbiol"},{"key":"BFcdd2016150_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijmm.2007.07.008","volume":"298","author":"CA Mohr","year":"2008","unstructured":"Mohr CA, Cicin-Sain L, Wagner M, Sacher T, Schnee M, Ruzsics Z et al. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int J Med Microbiol 2008; 298: 115\u2013125.","journal-title":"Int J Med Microbiol"},{"key":"BFcdd2016150_CR13","doi-asserted-by":"publisher","first-page":"12396","DOI":"10.1073\/pnas.1635160100","volume":"100","author":"D Yu","year":"2003","unstructured":"Yu D, Silva MC, Shenk T . Functional map of human cytomegalovirus AD169 defined by global mutational analysis. Proc Natl Acad Sci USA 2003; 100: 12396\u201312401.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcdd2016150_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1359-6101(03)00030-3","volume":"14","author":"CA Benedict","year":"2003","unstructured":"Benedict CA . Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev 2003; 14: 349\u2013357.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFcdd2016150_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.chom.2013.02.003","volume":"13","author":"W Smith","year":"2013","unstructured":"Smith W, Tomasec P, Aicheler R, Loewendorf A, Nemcovicova I, Wang EC et al. Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses. Cell Host Microbe 2013; 13: 324\u2013335.","journal-title":"Cell Host Microbe"},{"key":"BFcdd2016150_CR16","doi-asserted-by":"publisher","first-page":"e1004268","DOI":"10.1371\/journal.ppat.1004268","volume":"10","author":"S Verma","year":"2014","unstructured":"Verma S, Loewendorf A, Wang Q, McDonald B, Redwood A, Benedict CA . Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense. PLoS Pathogens 2014; 10: e1004268.","journal-title":"PLoS Pathogens"},{"key":"BFcdd2016150_CR17","doi-asserted-by":"publisher","first-page":"e1003224","DOI":"10.1371\/journal.ppat.1003224","volume":"9","author":"I Nemcovicova","year":"2013","unstructured":"Nemcovicova I, Benedict CA, Zajonc DM . Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. PLoS Pathogens 2013; 9: e1003224.","journal-title":"PLoS Pathogens"},{"key":"BFcdd2016150_CR18","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1038\/sj.onc.1203025","volume":"18","author":"GS Wu","year":"1999","unstructured":"Wu GS, Burns TF, McDonald ER, Meng RD, Kao G, Muschel R et al. Induction of the TRAIL receptor KILLER\/DR5 in p53-dependent apoptosis but not growth arrest. Oncogene 1999; 18: 6411\u20136418.","journal-title":"Oncogene"},{"key":"BFcdd2016150_CR19","doi-asserted-by":"publisher","first-page":"e67008","DOI":"10.1371\/journal.pone.0067008","volume":"8","author":"JS Chauhan","year":"2013","unstructured":"Chauhan JS, Rao A, Raghava GP . In silico platform for prediction of N-, O- and C-glycosites in eukaryotic protein sequences. PLoS One 2013; 8: e67008.","journal-title":"PLoS One"},{"key":"BFcdd2016150_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1097-2765(00)80207-5","volume":"4","author":"SG Hymowitz","year":"1999","unstructured":"Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. Triggering cell death: the crystal structure of Apo2L\/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563\u2013571.","journal-title":"Mol Cell"},{"key":"BFcdd2016150_CR21","doi-asserted-by":"crossref","first-page":"e19927","DOI":"10.1371\/journal.pone.0019927","volume":"6","author":"OM Shatnyeva","year":"2011","unstructured":"Shatnyeva OM, Kubarenko AV, Weber CE, Pappa A, Schwartz-Albiez R, Weber AN et al. Modulation of the CD95-induced apoptosis: the role of CD95 N-glycosylation. PLoS One 2011; 6: e19927.","journal-title":"PLoS One"},{"key":"BFcdd2016150_CR22","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/cddis.2010.61","volume":"1","author":"CR Reis","year":"2010","unstructured":"Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 2010; 1: e83.","journal-title":"Cell Death Dis"},{"key":"BFcdd2016150_CR23","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1158\/0008-5472.CAN-09-2889","volume":"70","author":"V Pavet","year":"2010","unstructured":"Pavet V, Beyrath J, Pardin C, Morizot A, Lechner M-C, Briand J-P et al. Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 2010; 70: 1101\u20131110.","journal-title":"Cancer Res"},{"key":"BFcdd2016150_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3324\/haematol.2011.046466","volume":"97","author":"G Jacquemin","year":"2012","unstructured":"Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morl\u00e9 A, Iessi E et al. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 2012; 97: 38\u201346.","journal-title":"Haematologica"},{"key":"BFcdd2016150_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1021\/nl503565t","volume":"15","author":"AB Zakaria","year":"2015","unstructured":"Zakaria AB, Picaud F, Rattier T, Pudlo M, Dufour F, Saviot L et al. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing. Nano Lett 2015; 15: 891\u2013895.","journal-title":"Nano Lett"},{"key":"BFcdd2016150_CR26","unstructured":"Dufour F, Rattier T, Constentinescu AA, Zischler L, Morl\u00e9 A, Ben Mabrouk H et al. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress Oncotarget (in press)."},{"key":"BFcdd2016150_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1084\/jem.20031457","volume":"199","author":"K Takeda","year":"2004","unstructured":"Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004; 199: 437\u2013448.","journal-title":"J Exp Med"},{"key":"BFcdd2016150_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2174\/157489211796957757","volume":"6","author":"S Shirley","year":"2011","unstructured":"Shirley S, Morizot A, Micheau O . Regulating TRAIL receptor-induced cell death at the membrane: a deadly discussion. Recent Pat Anticancer Drug Discov 2011; 6: 311\u2013323.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"BFcdd2016150_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/bph.12238","volume":"169","author":"O Micheau","year":"2013","unstructured":"Micheau O, Shirley S, Dufour F . Death receptors as targets in cancer. Br J Pharmacol 2013; 169: 1723\u20131744.","journal-title":"Br J Pharmacol"},{"key":"BFcdd2016150_CR30","doi-asserted-by":"publisher","first-page":"11265","DOI":"10.1158\/0008-5472.CAN-05-2801","volume":"65","author":"M MacFarlane","year":"2005","unstructured":"MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM . TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265\u201311270.","journal-title":"Cancer Res"},{"key":"BFcdd2016150_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0304-3835(91)90059-Q","volume":"57","author":"JW Rak","year":"1991","unstructured":"Rak JW, Basolo F, Elliott JW, Russo J, Miller FR . Cell surface glycosylation changes accompanying immortalization and transformation of normal human mammary epithelial cells. Cancer Lett 1991; 57: 27\u201336.","journal-title":"Cancer Lett"},{"key":"BFcdd2016150_CR32","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nchembio.999","volume":"8","author":"CD Rillahan","year":"2012","unstructured":"Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol 2012; 8: 661\u2013668.","journal-title":"Nat Chem Biol"},{"key":"BFcdd2016150_CR33","doi-asserted-by":"publisher","first-page":"11332","DOI":"10.1073\/pnas.1107385108","volume":"108","author":"YC Liu","year":"2011","unstructured":"Liu YC, Yen HY, Chen CY, Chen CH, Cheng PF, Juan YH et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc Natl Acad Sci USA 2011; 108: 11332\u201311337.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcdd2016150_CR34","doi-asserted-by":"publisher","first-page":"22982","DOI":"10.1074\/jbc.M110.211375","volume":"286","author":"AF Swindall","year":"2011","unstructured":"Swindall AF, Bellis SL . Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 2011; 286: 22982\u201322990.","journal-title":"J Biol Chem"},{"key":"BFcdd2016150_CR35","doi-asserted-by":"publisher","first-page":"43123","DOI":"10.1074\/jbc.M111.262741","volume":"286","author":"K Moriwaki","year":"2011","unstructured":"Moriwaki K, Shinzaki S, Miyoshi E . GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem 2011; 286: 43123\u201343133.","journal-title":"J Biol Chem"},{"key":"BFcdd2016150_CR36","doi-asserted-by":"publisher","first-page":"21337","DOI":"10.1074\/jbc.M608810200","volume":"282","author":"N Mazurek","year":"2007","unstructured":"Mazurek N, Jie Sun Y, Feng Liu K, Gilcrease MZ, Schober W, Nangia-Makker P et al. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) signaling by regulating PTEN in human breast carcinoma cells. J Biol Chem 2007; 282: 21337\u201321348.","journal-title":"J Biol Chem"},{"key":"BFcdd2016150_CR37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/cdd.2011.123","volume":"19","author":"N Mazurek","year":"2012","unstructured":"Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks J et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 2012; 19: 523\u2013533.","journal-title":"Cell Death Differ"},{"key":"BFcdd2016150_CR38","doi-asserted-by":"publisher","first-page":"4375","DOI":"10.1002\/cncr.26078","volume":"117","author":"N Mazurek","year":"2011","unstructured":"Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS . A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer 2011; 117: 4375\u20134380.","journal-title":"Cancer"},{"key":"BFcdd2016150_CR39","volume-title":"Essentials of Glycobiology","author":"A Varki","year":"2009","unstructured":"Varki A, Kannagi R, Toole BP . Glycosylation changes in cancer. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR et al (eds). Essentials of Glycobiology, 2nd edn. Cold Spring Harbor: New York, 2009."},{"key":"BFcdd2016150_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/glycob\/cwn105","volume":"19","author":"I Eude-Le Parco","year":"2009","unstructured":"Eude-Le Parco I, Gendronneau G, Dang T, Delacour D, Thijssen VL, Edelmann W et al. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009; 19: 68\u201375.","journal-title":"Glycobiology"},{"key":"BFcdd2016150_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2741\/e396","volume":"4","author":"A Harduin-Lepers","year":"2012","unstructured":"Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, Foulquier F, Groux-Degroote S, Delannoy P . Sialyltransferases functions in cancers. Front Biosci (Elite Ed) 2012; 4: 499\u2013515.","journal-title":"Front Biosci (Elite Ed)"}],"container-title":["Cell Death & Differentiation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/cdd2016150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2016150","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/cdd2016150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:10:34Z","timestamp":1684415434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cdd2016150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,10]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFcdd2016150"],"URL":"https:\/\/doi.org\/10.1038\/cdd.2016.150","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,10]]},"assertion":[{"value":"28 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}